ABIVAX specializes in therapeutic vaccines and antivirals, combining the technologies and the product portfolios of three French biotech companies financed by
The most advanced products in the portfolio of ABIVAX target a variety of major medical needs. They include: a therapeutic vaccine for chronic hepatitis B (which leads to cirrhosis and liver cancer) from CIGB and Wittycell; a novel anti-viral drug for AIDS from Splicos, an anti-HPV therapeutic vaccine to treat, without surgery, uterine cervix dysplasia and prevent the emergence of cancer from Wittycell, a novel adjuvant to boost NKT and B cell response from Wittycell. Thus, ABIVAX already has two therapeutic vaccines in development, one in a Phase IIb clinical trial in patients with chronic hepatitis B, and the other one expected to enter into a Phase I clinical trial in 2015 for the treatment of chronic infection with human papilloma virus and cervical dysplasia (an early stage in cervical cancer). The adjuvant is in Phase I clinical studies. In the field of AIDS, the company's first antiviral drug displays a novel mechanism of action, which might translate into a long-term effect on viral load reduction. It is scheduled to enter clinical trials in Q1 2014. Additional therapeutic vaccines are in preclinical development.
Caroline Carmagnol: +33 664-189-959